AT13148 - CAS# 1056901-62-2 60075 Inhibition of Dexamethasone-induced Fatty Liver

Inhibition of Dexamethasone-induced Fatty Liver Development by Reducing miR-17-5p Levels

allosteric inhibitor of Akt 1 and 2

Tiagabine for acute affective episodes in bipolar disorder

Molecular Weight: 861

such as NODI and NOD2

AT13148 - CAS# 1056901-62-2 60075 Inhibition of Dexamethasone-induced Fatty LiverAT13148, CAS No. 1056901 62 2, is a novel oral multi AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors. AT13148 is currently being developed by Astex Pharmaceuticals. AT131148 was identified utilizing high throughput X ray crystallography and fragment based lead discovery techniques. AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK and SGK